Background: Lymphocyte-predominant Hodgkin disease (LPHD) differs in biology and clinical behaviour from classic Hodgkin disease. Almost 100% of LPHD neoplastic cells express CD20 and thus rituximab could be effective; yet limited data are available.
Patients And Methods: We performed a retrospective analysis on patients with LPHD who were treated with rituximab at our institution to determine the magnitude of benefit offered by this drug.
Results: Seven patients were identified; 4 received the drug as single agent while the rest received it in combination with chemotherapy. All except 2 received the drug in the salvage setting. Response rate was 100% with 6 of 7 patients achieving complete remission. At a median follow-up of 2 years, 4 patients are still disease free while the rest relapsed at a median time of 27 months.
Conclusion: Rituximab is effective in LPHD and should be considered; however, the optimal schedule remains to be determined.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000177953 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disseminated nocardiosis in a patient with AIDS and B-cell non-Hodgkin's lymphoma: a case report.
BMC Infect Dis
January 2025
Department of Infectious Diseases, Hospital Universitario de Caracas, Caracas, Venezuela.
Background: Disseminated nocardiosis is a rare and potentially fatal disease, with a higher incidence in immunocompromised patients, such as those living with human immunodeficiency virus (HIV) or hematological malignancies, including lymphoma. Information on Nocardia spp. infection in Venezuela is limited.
View Article and Find Full Text PDFLymphomas With Primary Gastrointestinal Presentation: A Retrospective Study Covering a Five-Year Period at a Quaternary Care Center in Southern India.
Cureus
December 2024
Department of Histopathology and Cytology, Apollo Cancer Center, Chennai, IND.
Background and objective Lymphomas can involve the gastrointestinal (GI) tract as a primary disease or as a secondary spread of systemic disease. The GI tract is a key site for extranodal lymphomas, with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) occurring in this region. This study aimed to analyze the demography, anatomic distribution, histological subtypes, and immunomorphological characteristics of all lymphomas with a primary GI presentation at a quaternary care hospital in southern India.
View Article and Find Full Text PDFImpact of circulating lymphoma cells at diagnosis on outcomes in patients with newly diagnosed de novo diffuse large B-cell lymphoma.
J Hematol Oncol
January 2025
Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH, USA.
Diffuse large B-cell lymphoma (DLBCL), the most common B-cell non-Hodgkin lymphoma rarely presents with circulating lymphoma cells (CL) at diagnosis. Previous studies were limited by small sample size precluding robust analysis. Hence, we evaluated the prognostic relevance of CL cells in newly diagnosed DLBCL patients.
View Article and Find Full Text PDFClinical features and temporal trends in H. pylori negative gastric maltoma.
Arab J Gastroenterol
January 2025
Division of Gastroenterology and Hepatology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. Electronic address:
Article Synopsis
- Mucosa-Associated Lymphoid Tissue (MALT) lymphoma, particularly gastric MALToma, is often associated with Helicobacter pylori (H. pylori) infection, though a significant number of cases occur without it.
- A study analyzed 52 patients with gastric MALToma from 2000 to 2021, finding that 48.1% were H. pylori-negative (HPN) and noted trends of increased HPN diagnoses in more recent years.
- Treatment outcomes showed that HPP patients had better responses to eradication therapy compared to HPN patients, who were more likely to receive additional chemo or radiotherapy.
- Despite these differences in treatment response, clinical features between HPP and HPN patients
Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review.
Leuk Lymphoma
January 2025
Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Follicular lymphoma (FL) represents the second most frequent type of non-Hodgkin lymphoma and the most common indolent histology. The disease course of FL is heterogeneous, likely resulting from diverse molecular and immunological features that drive a broad spectrum of clinical presentations. While some patients with low-volume and asymptomatic disease are suitable for observation, patients with high tumor burden, advanced-stage, or symptomatic disease more often necessitate treatment initiation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!